Skip to main content
OpenTrials
Completed

NCT Number: NCT06998277

Impact of the Novel UC-TREAT Diet on the Gut Microbiome and Its Acceptability in Healthy Adults and Adults With Quiescent Ulcerative Colitis

This will be an open-label dietary intervention study recruiting both healthy adults (≥16y) and adults with quiescent Ulcerative Colitis (UC). The study will span a total of 25 days and is divided into two phases; a 10-day run-in observation period (day -10 to day 0), during which the participant continues with their normal diet, and a 15-day dietary intervention period (day 0 to day 15), during which they will consume a diet high in specific high-fibre foods, fermented foods, berries, and a multivitamin-multimineral tablet. Throughout the study, participants will be asked to provide 3 blood samples (at days -10, 0, and 15), 4 stool and urine samples (at days -15, 0, 10, and 15), and to record a total of 6 days of food intake in provided food diaries. Disease activity, gastrointestinal symptoms, and quality of life will be assessed on 4 occasions (days -10, 0, 10, and 15) via validated questionnaires, and diet acceptability will be assessed at the end of the study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Glasgow

Glasgow, G31 2ER, United Kingdom

About this study

This will be an open-label dietary intervention study recruiting both healthy adults (≥16y) and adults with quiescent Ulcerative Colitis (UC) . The study will span a total of 25 days and is divided into two phases; a 10-day "run-in" observational period and a 15-day dietary intervention period.

During the 10-day "run-in" observational period (day -15 to day 0), participants will be asked to continue with their regular habitual diet and record their food intake in a provided estimated weight food diary with food photography for the first 3 of the 10 days. After this "run-in" period, participants will start the 15-day UC-TREAT dietary intervention (day 0 to day 15), where they will consume daily micronutrient supplements, increase intake of berries, and gradually increase intake of dietary fibre and fermented foods.

For the first 5 days of the dietary intervention, participants will enter a "ramping" phase, where, with the guidance of the researchers, they will consume 2 portions of berries (blueberries and raspberries) and 1 multivitamin-multimineral tablet each day. Participants will increase their fibre intake by 1 serving of high-fibre food per day until they reach an additional intake of 35g/d and increase fermented food intake by approximately 1 serving per day until they reach at least 5 servings per day. For the final 10 days of the UC-TREAT dietary intervention, participants will enter a "maintenance phase", where they will maintain this additional 35g of fibre intake and at least 5 servings of fermented foods daily. Participants will be asked to record 3 days of food intake in the provided food diaries during this period. The purpose of the ramping period is to reduce the sudden onset of functional abdominal symptoms typically associated with a rapid increase in dietary fibre consumption, including flatulence, bloating, and abdominal cramping. Throughout the study, participants will be asked to provide 3 blood samples (at days -10, 0 and 15), 4 stool and urine samples (at days -10, 0, 10, and 15), and to record a total of 6 days of food intake in provided food diaries.

On 4 occasions (days -10, 0, 10, and 15), all participants will be asked to complete a questionnaire assessing their gastrointestinal symptoms (GSRS-IBS), while participants with UC will also be asked to complete a questionnaire assessing their disease-specific quality of life (sIBDQ) and self-reported disease activity (SCCAI). At the end of the study (day 15), all participants will also be asked to complete an acceptability questionnaire to assess their tolerance of the diet.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Individuals with Ulcerative Colitis:

  • Confirmed diagnosis of Ulcerative Colitis
  • ≥16 years of age
  • Motivated to follow the prescribed diet for the study period

Healthy controls:

  • ≥16 years of age
  • Motivated to follow the prescribed diet for the study period

Exclusion criteria

Individuals with Ulcerative Colitis:

  • Self-reported active disease (SCCAI≥5) and/or a score ≥2 on any variable within SCCAI
  • Previous surgery related to their UC (e.g. colectomy)
  • Adjustment of medication dose in the previous month
  • Initiation of a new medication in the prior 3 months
  • BMI≥35kg/m2
  • Pregnancy or lactation
  • Regular use of pre/probiotic supplements
  • Antibiotics or steroid use in the past 2 months
  • Weight fluctuations ≥ 2kg in the past month
  • Dietary restrictions (vegetarian, vegan, gluten-free etc)
  • Participation in other interventional research.

Healthy controls:

  • Regular use of medication or regular visits to a physician
  • History of gut surgery
  • BMI≥35kg/m2
  • Pregnancy or lactation
  • Regular use of pre/probiotic supplements
  • Antibiotics or steroid use in the past 2 months
  • Weight fluctuations ≥ 2kg in the past month
  • Dietary restrictions (vegetarian, vegan, gluten-free etc)
  • Participation in other interventional research.

Treatment and study plan

Dietary therapy

Other

Participants with quiescent UC will undergo a 10-day "observational" period followed by 15-days of the UC-TREAT dietary intervention. Disease activity, quality of life, and gastrointestinal symptoms will be assessed throughout

Primary outcomes

  1. Change in faecal butyrate concentration

    Time frame: At day -10, day 0, day 10, and day 15

    Change faecal butyrate concentration at the end of the diet (day 15) compared to baseline (day 0) and control (day -10).

  2. Gastrointestinal symptoms

    Time frame: At day -10, day 0, day 10, and day 15

    Change in gastrointestinal symptoms compared to baseline, assessed via the GI Symptom Rating Scale (GSRS-IBS), will be used to assess GI tolerance of the diet. The GSRS-IBS assesses GI symptoms in 5 domains: pain, bloating, constipation, diarrhoea, and satiety, where a score increase indicates symptom increase.

Secondary outcomes

  1. Faecal metabolites

    Time frame: At day -10, day 0, day 10, and day 15.

    Targeted faecal metabolites will be assessed via gas chromatography, colorimetry, and NMR metabolomics to evaluate changes to the faecal metabolome throughout the study period

  2. Faecal microbiota diversity

    Time frame: At day -10, day 0, day 10, and day 15

    Change in faecal microbiota alpha-diversity during the diet compared to baseline and control.

  3. Faecal microbiota composition

    Time frame: At day -10, day 0, day 10, and day 15

    Change in faecal microbiota composition (beta-diversity and taxa abundance) during the diet compared to baseline and control, as well as the differences between participants with UC and healthy controls.

  4. Faecal calprotectin

    Time frame: At day -10, day 0, day 10, and day 15.

    Faecal calprotectin will be measured in all participants to assess any changes in gut inflammation throughout the study.

  5. Blood inflammatory markers

    Time frame: At day -10, day 0 and day 15.

    Biomarkers of inflammation in plasma, such as C-reactive protein, will be measured in fasted blood samples.

  6. Clinical disease activity

    Time frame: At day -10, day 0, day 10, and day 15.

    Clinical disease activity will be assessed via the Simple Clinical Colitis Activity Index (SCCAI), where a score increase indicates disease worsening and a score ≥ 5 indicates active disease.

  7. Diet acceptability

    Time frame: Once at the end of the study period (day 15).

    Acceptability of the diet will be assessed in all participants at the end of the study, using a study specific 9-item questionnaire employing a 5-point likhert scale ("Strongly Agree", "Agree", "No opinion", "Disagree", "Strongly Disagree").

  8. Quality of life (sIBDQ)

    Time frame: At day -10, day 0, day 10, and day 15.

    Quality of life will be assessed in participants with Ulcerative Colitis via the short-Inflammatory Bowel Disease Questionnaire (sIBDQ). This questionnaire assesses QoL in 4 domains: bowel, social, emotional, and systemic, where a score increase indicates improve quality of life.

  9. Dietary adherence

    Time frame: Throughout the dietary intervention period (~15 days).

    Adherence to the prescribed diet will be assessed using daily food checklists.

  10. Dietary intake

    Time frame: 3 days on 2 occasions (6 days in total) throughout the entire study period (~25 days).

    Dietary intake will be assessed via 3-day, estimated-portion food diaries supplemented with food photography. Food diaries will be recorded during the observational phase and during the dietary intervention phase of the study.

  11. Stool form

    Time frame: At day -10, day 0, day 10, and day 15.

    Bristol Stool Chart Rating (BSCR) and percentage water content will be assessed to inform of any changes to stool form throughout the study.

  12. Body composition

    Time frame: At day -10, day 0 and day 15.

    BMI and %fat mass will be assessed throughout the study to evaluate any changes to body composition throughout the study.

Sponsors and collaborators

Lead sponsor

University of Glasgow

Other

Registry information

Acronym: UC-TREAT

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 31, 2025
Registry last updated
Mar 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.